DSP-2342 is potent, selective 5-hydroxytryptamine 2A/7 (5-HT2A/5-HT7) receptor antagonist with binding Ki of 1.15 nM and 2.92 nM for human 5-HT2A and 5-HT7 respectively, IC50 of 24.8 nM and 4.4 nM.
DSP-2342 shows weak affinity for D2 receptors Ki values of 112 and 196 nM for the D2L and D2S receptors, respectively, also shows low affinity for receptors commonly implicated in antipsychotic-related adverse effects, including human adrenergic α1, histamine H1, and 5-HT2C re ceptors.
DSP-2342 possesses antipsychotic, anxiolytic, mood-stabilizing, and antidepressant signatures.
DSP-2342 suppressed phencyclidine- induced hyperlocomotion in mice, reduced freezing in rat contextual fear conditioning test.
DSP-2342 also attenuated aggressive behavior in resident-intruder test in Alzheimer disease model mice.
DSP-2342 restored cognitive performance in another Alzheimer disease model mice, as assessed by the novel object recognition test.
DSP-2342 increased extracellular levels of noradrenaline, dopamine, and glutamate in the medial prefrontal cortex.